Overview

A Study of LY3025876 in Participants With Diabetes

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Liraglutide